Vasculopathic Injury and Plasma as Endothelial Rescue - OCTAplas Trial (EudraCT no. 2014-000452-28)
NCT ID: NCT02253082
Last Updated: 2016-12-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
44 participants
INTERVENTIONAL
2014-11-30
2016-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Background
* Patients operated for thoracic aortic dissections in deep hypothermic circulatory arrest are prone to develop postoperative renal failure secondary to severe endothelial dysfunction and capillary leakage, and currently no therapy addressing this complication has proven successful
* Data from animal models of shock and massively bleeding patients indicate that plasma may be beneficial for re-establishing endothelial integrity
* Patients operated for thoracic aortic dissections generally develop requirement for massive transfusion during surgery
* Current guidelines, however, recommend against plasma transfusion to patients not needing coagulation factor replacement due to the inherent risk of transfusion complications
* OctaplasLG® is an immune complex-free and cell-free, pathogen inactivated standardized plasma product that has been shown not to be related to the transfusion complications seen secondary to standard fresh frozen plasma (FFP), thus, OctaplasLG® may be a beneficial, alternative resuscitation fluid in patients with severe endothelial dysfunction/damage
* The purpose is to bridge the knowledge gap regarding the effect of OctaplasLG® on endothelial integrity and safety
Design Single-centre randomised, single-blinded, controlled, investigator-initiated pilot trial of 42 patients undergoing emergency surgery for thoracic aortic dissections randomized to administration of OctaplasLG®, as compared to standard FFP, as coagulation factor replacement related to bleeding, when need for coagulation factor replacement is deemed necessary by the clinician according to local protocol.
Inclusion criteria
* Patient eligible for emergency surgery on cardiopulmonary bypass pump for a thoracic aortic dissections AND
* Age \> 18 years AND
* Consent obtainable from patient or by proxy (independent physicians and/or next of kin)
Exclusion criteria
* Documented refusal of blood transfusion OR
* FFP transfusion before randomization OR
* Aortic dissection due to trauma OR
* Treatment with GPIIb/IIIa inhibitors \< 24h from screening OR
* Withdrawal from active therapy OR
* Expected to die \< 24h OR
* Previously within 30 days included in a randomized trial, if known at the time of enrolment.
* Known immunoglobulin A (IgA) deficiency with documented antibodies against IgA
* Known hypersensitivity to OctaplasLG®: the active substance, any of the excipients (Sodium citrate dihydrate, Sodium dihydrogenphosphate dihydrate or Glycine) or residues from the manufacturing process (Tri (N-Butyl) Phosphate (TNBP) and Octoxynol (Triton X-100))
* Known severe deficiencies of protein S
* Pregnancy (non-pregnancy confirmed by patient being postmenopausal or having a negative serum-hCG).
Randomization Blood Bank staff will perform 24 hour on-site randomisation by envelope-opening to allow for immediate allocation to either receiving OctaplasLG® (intervention) or standard FFP (control) as coagulation factor replacement.
Outcome measures
Primary outcome measure:
• Plasma levels of endothelial markers (Syndecan-1, soluble thrombomodulin (sTM), sE-selectin, sVE-cadherin) at 24 hours after arrival in ICU for postoperative care, as compared to baseline
Secondary outcome measures:
* Plasma levels of endothelial markers (Syndecan-1, sTM, sE-selectin, sVE-cadherin) at 48 hours postoperatively, as compared to baseline
* Acute Kidney Injury (AKI) according to RIFLE Criteria in the first 7 postoperative days, see appendix 1
* Renal replacement therapy
* Sepsis-Related Organ Failure Assessment (SOFA), worst score during ICU stay, see appendix 2
* 30-day and 90-day mortality
* P-CRP, IL-6, P-Catecholamines at 24 hours and 48 hours
* Length of stay in ICU and hospital
* Severe adverse reactions
Tertiary outcome measures
* TRALI
* TACO
Trial size The calculation is based in part by data collected in a quality control investigation of the effect of OctaplasLG® vs. FFP. The power calculation is based on the finding of a significantly higher relative level of sTM in the FFP compared to the OctaplasLG® group (p=0.025). The relative values of sTM post-CPB: FFP group: mean 3.35 (SD 2.12); OctaplasLG® group: mean 1.70 (SD 0.49); SD across the entire group of patients: 1.574. To detect the above difference with a power of 0.90 (1-β) and alpha of 0.05 requires n=21 patients in each group. The investigators have chosen to include 42 patients, 21 evaluable patients in each randomization group in case of attrition, in the present trial.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
FACTORIAL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
OctaplasLG®
replacement to bleeding
OctaplasLG®
OctaplasLG® is an industrial donor plasma product pooled from approximately 400 single donor units. It possess' unique features when compared to standard FFP, such as having standardized concentrations of natural pro- and anti-coagulation factors, standardized volume and as being pathogen free. Very importantly, the manufacturing method of OctaplasLG® removes immune complexes and cells in several steps of microfiltration in addition to viral, bacterial and prion pathogen inactivation.
Standard fresh frozen plasma
replacement to bleeding
Fresh frozen plasma
Standard FFP from the Blood Bank
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
OctaplasLG®
OctaplasLG® is an industrial donor plasma product pooled from approximately 400 single donor units. It possess' unique features when compared to standard FFP, such as having standardized concentrations of natural pro- and anti-coagulation factors, standardized volume and as being pathogen free. Very importantly, the manufacturing method of OctaplasLG® removes immune complexes and cells in several steps of microfiltration in addition to viral, bacterial and prion pathogen inactivation.
Fresh frozen plasma
Standard FFP from the Blood Bank
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age \> 18 years AND
* Consent obtainable from patient or by proxy (independent physicians and/or next of kin)
Exclusion Criteria
* FFP transfusion before randomization OR
* Aortic dissection due to trauma OR
* Treatment with GPIIb/IIIa inhibitors \< 24h from screening OR
* Withdrawal from active therapy OR
* Expected to die \< 24h OR
* Previously within 30 days included in a randomized trial, if known at the time of enrolment
* Known IgA deficiency with documented antibodies against IgA
* Known hypersensitivity to OctaplasLG®: the active substance, any of the excipients (Sodium citrate dihydrate, Sodium dihydrogenphosphate dihydrate or Glycine) or residues from the manufacturing process (Tri (N-Butyl) Phosphate (TNBP) and Octoxynol (Triton X-100))
* Known severe deficiencies of protein S
* Pregnancy (non-pregnancy confirmed by patient being postmenopausal or having a negative serum-hCG)
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Octapharma
INDUSTRY
Rigshospitalet, Denmark
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jakob Stensballe, MD, PhD
MD, PhD, Consultant
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jakob Stensballe, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Rigshospitalet, Denmark
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Rigshospitalet, Copenhagen University Hospital
Copenhagen, , Denmark
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Stensballe J, Ulrich AG, Nilsson JC, Henriksen HH, Olsen PS, Ostrowski SR, Johansson PI. Resuscitation of Endotheliopathy and Bleeding in Thoracic Aortic Dissections: The VIPER-OCTA Randomized Clinical Pilot Trial. Anesth Analg. 2018 Oct;127(4):920-927. doi: 10.1213/ANE.0000000000003545.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
H-3-2014-018
Identifier Type: OTHER
Identifier Source: secondary_id
VIPER-OCTA
Identifier Type: -
Identifier Source: org_study_id